# Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

Study · id `cardio:ct-nct05976893` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05976893](<https://clinicaltrials.gov/study/NCT05976893>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05976893

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 620 participants.

## Technical summary

Registry record NCT05976893. Randomized; single masking; primary purpose treatment. Start 2023-08-01 (anticipated); primary completion 2025-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 620 participants (planned count; ClinicalTrials.gov record NCT05976893, source copy `cardio:ctgov-nct05976893-2023-08-04`, retrieved 2026-10-31)
- Planned start: 2023-08-01 (anticipated) (ClinicalTrials.gov record NCT05976893, source copy `cardio:ctgov-nct05976893-2023-08-04`, retrieved 2026-10-31)
- Primary completion: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT05976893, source copy `cardio:ctgov-nct05976893-2023-08-04`, retrieved 2026-10-31)
- Completion: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT05976893, source copy `cardio:ctgov-nct05976893-2023-08-04`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05976893-2023-08-04`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer
- Condition: ASCVD
- Condition: Atherosclerotic Cardiovascular Disease
- Condition: Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
- Condition: Cancer
- Intervention (Drug): Evolocumab
- Intervention (Drug): Statin
- Lead sponsor: Xiang Xie
- Lead sponsor class: OTHER
- Collaborator: Xinjiang Medical University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)

## Provenance

Content hash: 7d10a0b5fe977fa51c1fb66b1cabe333007d3a4f1710c89bd1e7e8cd9829f9e6
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
